MedTrace Logo

Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD

NCT07378280 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2026-01-30

No results posted yet for this study

Summary

A study for evaluating the safety and efficacy of L. lactis CKDB001 on liver aminotransferases in subjects with nonalcoholic fatty liver disease

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

Probiotics (L. lactis CKDB001)

L. lactis CKDB001: Enteric coated capsule with L. lactis CKDB001, daily, 12 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo: Enteric coated capsule without any probiotics, daily, 12 weeks

Sponsors & Collaborators

  • Chong Kun Dang Bio

    collaborator UNKNOWN

  • Chuncheon Sacred Heart Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2023-08-02
Completion
2023-11-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07378280 on ClinicalTrials.gov